权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Birc5 as a regulator of NK cell development and immune function

Birc5 作为 NK 细胞发育和免疫功能的调节剂

基本信息

批准号：
10066361
负责人：
Aimee Melissa Beaulieu
金额：
$ 38.96万
依托单位：
RBHS-NEW JERSEY MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10066361
关键词：
Adoptive Cell Transfers Adoptive Transfer Anti-Inflammatory Agents Antiviral Agents BIRC5 gene Bone Marrow Cell Line Cell Nucleus Cell Proliferation Cell Therapy Cell physiology Cells Cellular biology Cellular immunotherapy Clinic Clinical Clinical Trials Cues Cytoplasm Data Development Environment FRAP1 gene Family member Future Generations Genetic Techniques Goals Growth Growth Factor Hematopoiesis Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Homeostasis Human Immune Immune response Immunity Immunocompromised Host Immunotherapeutic agent Impairment In Vitro Infection Inflammatory Interleukin-12 Interleukin-15 Interleukin-18 Interleukin-2 Investigation Longevity Lymphocyte Malignant Neoplasms Mediating Memory Metabolic Metabolism Mitochondria Mitosis Molecular Molecular Genetics Mus Natural Killer Cells Pathway interactions Peripheral Pharmacology Population Process Production Property Regimen Regulation Role Signal Pathway Signal Transduction Testing Tissues Transforming Growth Factor beta Transgenic Mice Virus Virus Diseases Xenograft Model base cancer cell cancer therapy cytokine experimental study extracellular gain of function immune function in vivo infection related cancer inhibitor-of-apoptosis protein innovation novel overexpression pathogen pathogenic virus progenitor sensor single-cell RNA sequencing stem stem cells tumor

项目摘要

ABSTRACT Natural Killer (NK) cells are cytotoxic lymphocytes that mediate immune defense against viral pathogens and tumors. In clincial settings, NK cells are being targeted in adoptive cell transfer (ACT) and hematopoietic stem cell transplantation (HSCT) regimens, and immunotherapeutic approaches, to treat cancer and cancer-related infections. Effective NK cell immunity is predicated on the sustained presence of a pool of functional NK cells in the periphery. At steady state, the NK cell niche is maintained by the continual development of new NK cells from progenitor populations in the bone marrow and by the homeostatic expansion of mature NK cells in the periphery. In addition, certain inflammatory signals may transiently expand effector NK cells needed for protection during infection or malignancy. Understanding the molecular pathways that control these processes will critically impact the development of novel and more effective NK cell-based therapies in the clinic. Our preliminary studies have highlighted a critical role for the Inhibitor of Apoptosis Protein (IAP), Birc5, in NK cell hematopoiesis and function. Prior studies in stem cells and cancer cells have shown that Birc5 contributes to a broad range of cellular functions, including mitosis, survival, and cellular metabolism, acting through its highly compartmentalized activities in the nucleus, cytoplasm, and mitochondria, respectively. A role for Birc5 in NK cell biology has not been described. New data in our lab indicate that Birc5 is highly and transiently upregulated in NK cells undergoing expansion in the context of development in the bone marrow, or viral infection in the periphery. Further, our preliminary studies indicate that Birc5-deficiency severely impairs mouse NK cell development and maturation. The specific cellular functions of Birc5 in NK cells, as well as its roles in homeostatic- and infection-related NK cell expansion remain to be defined. Thus, we will conduct studies that test the central hypothesis that Birc5 acts downstream of key cytokine and metabolic growth signals to orchestrate NK cell expansion during development and peripheral immunity. These studies will utilize novel transgenic mice, in which the Birc5 gene can be deleted in NK cells in a cell-specific or conditional manner, to investigate the contributions of Birc5 to NK cell proliferation, survival, and metabolic function in settings of development, homeostatic expansion, and anti-viral immune responses in vivo. Further, we will combine sophisticated molecular and genetic techniques to define the environmental cues and intracellular signaling networks that modulate Birc5 function in NK cells. And finally, we will use an innovative mouse xenograft model to study Birc5 function in human NK cells in vivo. Ultimately, our studies have the potential to inform ongoing and future NK cell-based immunotherapies, including adoptive cell transfer (ACT) and hematopoietic stem cell transfer (HSCT) regimens that harness the anti-tumor properties of NK cells to treat cancer. !

摘要